A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors

Cardio-Oncology

Sherry-Ann Brown¹  Patrick Collier²  Jessica Castrillon Lal³  Feixiong Cheng⁴ 

[1] Cardio-Oncology Program, Division of Cardiovascular Medicine, Medical College of Wisconsin, 53226, Milwaukee, WI, USA;Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, 44195, Cleveland, OH, USA;Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Cleveland Clinic, Sydell and Arnold Miller Family Heart and Vascular Institute, 44195, Cleveland, OH, USA;Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, 44195, Cleveland, OH, USA;Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, 44195, Cleveland, OH, USA;Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, 44195, Cleveland, OH, USA;Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, 44195, Cleveland, OH, USA;Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 44106, Cleveland, OH, USA;

关键词: Cardio-oncology;    Cardiotoxicity;    Immune checkpoint inhibitors;    Immunotherapy;    Myocardial infarction;    Myocarditis;   

DOI  :  10.1186/s40959-021-00106-x

来源: Springer

【 摘 要 】

BackgroundModern therapies in oncology have increased cancer survivorship, as well as the incidence of cardiovascular adverse events. While immune checkpoint inhibitors have shown significant clinical impact in several cancer types, the incidence of immune-related cardiovascular (CV) adverse events poses an additional health concern and has been reported.MethodsWe performed a retrospective analysis of the FDA Adverse Event Reporting System data of suspect product reports for immunotherapy and classical chemotherapy from January 2010–March 2020. We identified 90,740 total adverse event reports related to immune checkpoint inhibitors and classical chemotherapy.ResultsWe found that myocarditis was significantly associated with patients receiving anti-program cell death protein 1 (PD-1) or anti-program death ligand 1 (PD-L1), odds ratio (OR) = 23.86 (95% confidence interval [CI] 11.76–48.42, (adjusted p-value) q <  0.001), and combination immunotherapy, OR = 7.29 (95% CI 1.03–51.89, q = 0.047). Heart failure was significantly associated in chemotherapy compared to PD-(L)1, OR = 0.50 (95% CI 0.37–0.69, q <  0.001), CTLA4, OR = 0.08 (95% CI 0.03–0.20, q <  0.001), and combination immunotherapy, OR = 0.25 (95% CI 0.13–0.48, q <  0.001). Additionally, we observe a sex-specificity towards males in cardiac adverse reports for arrhythmias, OR = 0.81 (95% CI 0.75–0.87, q <  0.001), coronary artery disease, 0.63 (95% CI 0.53–0.76, q <  0.001), myocardial infarction, OR = 0.60 (95% CI 0.53–0.67, q <  0.001), myocarditis, OR = 0.59 (95% CI 0.47–0.75, q <  0.001) and pericarditis, OR = 0.5 (95% CI 0.35–0.73, q <  0.001).ConclusionOur study provides the current risk estimates of cardiac adverse events in patients treated with immunotherapy compared to conventional chemotherapy. Understanding the clinical risk factors that predispose immunotherapy-treated cancer patients to often fatal CV adverse events will be crucial in Cardio-Oncology management.

【 授权许可】

CC BY